7 Leading MedTech Stocks for Next-Gen Health Solutions

MedTech Industry Overview - The MedTech industry reached a valuation of $503.2 billion in 2022 and is projected to grow to$776.5 billion by 2033, implying a CAGR of 4.4% [1] - Key growth areas over the next five years include cardiovascular health, digital healthcare, and robotics [1] - Rising global prevalence of chronic conditions like diabetes, cardiovascular disease, and obesity is driving MedTech relevance [1] Johnson & Johnson (JNJ) - J&J operates in pharmaceuticals and medical devices, covering orthopedics, surgery, interventional solutions, and vision care [3] - The company posted an average EPS of $2.62 in the past year, beating consensus estimates by 3.28$10.71 and revenue of $91.11 billion by fiscal 2025 [4] Abbott Laboratories (ABT) - Abbott offers solutions in diagnostics, nutrition, pharmaceuticals, and medical devices, with a strong presence in cardiovascular and diabetes care [5][6] - The company achieved an average EPS of$1.11 in the past year, slightly beating consensus estimates by 2.6% [6] - ABT stock trades at 4.5X sales, with analysts forecasting 5% EPS growth to $4.66 and 4.1$41.74 billion by year-end [7] Edwards Lifesciences (EW) - Edwards specializes in structural heart diseases, focusing on heart valve replacement technologies and critical care monitoring systems [8] - The company posted an average EPS of 65 cents, beating consensus estimates by 1 cent [8] - EW stock trades at 6.72X trailing-year sales, with analysts projecting 8% EPS growth to $2.70 and 6.4$6.39 billion by year-end [9] Glaukos (GKOS) - Glaukos develops devices and therapeutics for glaucoma, corneal disorders, and retinal diseases, pioneering micro-invasive glaucoma surgery [10] - The company reported a loss per share of 60 cents in the past year, worse than the anticipated 56-cent loss [10] - GKOS stock trades at 18X sales, with analysts projecting significant revenue growth to $451.62 million by fiscal 2025 [10] Inari Medical (NARI) - Inari develops minimally invasive catheter-based devices for venous diseases, including its LimFlow product for chronic limb-threatening ischemia [11] - The company posted an average loss per share of 5 cents, better than the expected 8-cent loss [11] - NARI stock trades at 5.89X sales, with analysts forecasting 21.3$598.72 million by 2024 [12] iRhythm Technologies (IRTC) - iRhythm specializes in ambulatory cardiac monitoring services, known for its Zio Monitor patch for arrhythmia detection [13] - The company reported a loss per share of $1, worse than the expected 74-cent loss [13] - IRTC stock trades at 5.3X sales, with analysts projecting 18.4$583.5 million by fiscal 2024 [14] SI-Bone (SIBN) - SI-Bone offers minimally invasive surgical implants for sacroiliac joint dysfunction [15] - The company posted an average loss per share of 27 cents, better than the expected 33-cent loss [15] - SIBN stock trades at 4.19X sales, with analysts forecasting 18.8% revenue growth to $165.05 million by year-end and further growth to$191.54 million in the following year [16]